The longevity corner of the book

Scattered through the encyclopedia section of The Complete Guide to Peptides are a handful of entries that belong to the most exciting frontier in ageing research. FOXO4-DRI. Humanin. MOTS-c. SS-31. Epitalon (covered in Part 4).

You will hear these names more and more. This article explains the science behind them, which is genuinely fascinating, and where each one actually stands.

Zombie cells

Start with an idea that has changed how scientists think about ageing: cellular senescence.

When a cell is damaged or has divided too many times, it can enter a state where it stops dividing but does not die. These senescent cells hang around. Worse, many of them release a cocktail of inflammatory signals that damage the tissue around them. Researchers sometimes call them "zombie cells": not alive in the useful sense, not dead, and harmful to their neighbours.

Senescent cells accumulate with age, and in animal studies, clearing them out has improved a range of age-related problems. That has launched a whole field searching for senolytics, drugs that selectively kill senescent cells while sparing healthy ones.

FOXO4-DRI: a peptide designed to kill zombie cells

The book's entry on FOXO4-DRI describes one of the most elegant senolytic ideas.

Senescent cells avoid dying partly because a protein called FOXO4 holds on to p53, the cell's key "self-destruct" regulator, keeping it in the nucleus where it prevents the cell from triggering its own death. The book summarises the mechanism accurately: FOXO4-DRI disrupts the interaction between FOXO4 and p53, releasing p53 and pushing senescent cells into programmed cell death.

The "DRI" stands for D-Retro-Inverso. It describes a clever chemical trick: the peptide is built from mirror-image amino acids in reversed order. The result has a similar shape to the natural sequence but is much harder for the body's enzymes to break down.

The landmark study, published in 2017 in the journal Cell, found that FOXO4-DRI restored fitness, fur density and kidney function in aged mice and in mice with accelerated ageing.

The book is appropriately cautious here, noting early research suggests it is well tolerated in animal models and that further human studies are required. That is correct. There are no completed human trials establishing safety or benefit. Deliberately switching on p53-driven cell death is powerful biology, and powerful biology needs human safety data before anyone should be injecting it.

The peptides hidden in your mitochondria

The next idea is even more surprising.

Mitochondria, the energy producing structures in your cells, have their own small genome, separate from the DNA in the nucleus. For decades it was thought this mitochondrial DNA only coded for a small, known set of proteins involved in energy production. Then researchers found short peptides encoded within it that nobody had noticed. These are called mitochondrial-derived peptides.

The book covers two:

Humanin was the first discovered, in 2001. The book describes it as protecting mitochondria and cells from oxidative stress and damage, with research interest in neurodegeneration, heart health and ageing. (A small correction: the book says humanin was first discovered in the hypothalamus. It was actually first identified in work on brain tissue from a person with Alzheimer's disease, which is part of why neuroprotection became its main research theme.)

MOTS-c was identified later. The book describes it as regulating metabolism, improving insulin sensitivity and fat oxidation. In mouse studies it has acted a bit like an "exercise signal", improving metabolic markers, and levels of it rise in human muscle during exercise.

The discovery that our mitochondria send out their own hormone-like signals is genuinely one of the more remarkable findings in recent biology. It means the cell's power stations are not just generators. They talk to the rest of the body.

SS-31: the one that went furthest

SS-31, also known as elamipretide, is the mitochondrial peptide in the book that has travelled furthest through human research.

The book's description of its mechanism is accurate: it binds to cardiolipin, a fat molecule found almost exclusively in the inner membrane of mitochondria, stabilising the membrane and supporting energy production. Cardiolipin is crucial for the machinery that makes ATP, the cell's energy currency.

Unlike most of the longevity compounds in this book, elamipretide has been through multiple human clinical trials, including in heart failure, mitochondrial myopathy and the rare genetic disease Barth syndrome, which is caused by faulty cardiolipin. The results in common conditions have been mixed, with several trials missing their main goals. The strongest case has been in Barth syndrome, where the mechanism matches the disease directly.

That is a useful lesson in itself. A compound can have an excellent mechanism, reach human trials, and still struggle to show benefit in broad conditions, while working best where its biology fits one specific disease precisely.

What the book gets right, and the gap

The book's longevity entries are accurate on mechanism and, in the FOXO4-DRI case, appropriately cautious. That is to its credit.

Where they fall short is in dosing. The entries give specific doses for all of these compounds, such as SS-31 at 10 to 20 mg weekly or FOXO4-DRI at 5 to 10 mg per week. For compounds without established human dosing, those numbers cannot have come from approved prescribing information. Part 7 looks at where the book's dosing comes from.

The takeaway

This corner of the book points at real, exciting science. Senescent cells, mitochondrial-derived peptides and cardiolipin-targeted drugs are serious research areas at leading universities and companies.

The right way to follow them is as science news, not shopping lists. Watch for human trial results. Notice the difference between "restored fur in mice" and "improved outcomes in people". And when a compound does reach human trials, as SS-31 has, pay attention to what actually happened, because that is where you learn whether a beautiful mechanism translates into a real benefit.

This series reviews a consumer book, not a clinical guideline. Many compounds it discusses are not approved for human use in most countries. Nothing here is medical advice or a recommendation to use any substance. Speak to a qualified clinician before starting anything.